BiotechTube

Interferon beta-1a

ApprovedCompleted
1 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Multiple Sclerosis, Relapsing, Remitting

Conditions

Multiple Sclerosis, Relapsing, Remitting

Trial Timeline

Jan 1, 2005 → Jul 1, 2010

NCT ID
NCT01201343

About Interferon beta-1a

Interferon beta-1a is a approved stage product being developed by Merck for Multiple Sclerosis, Relapsing, Remitting. The current trial status is completed. This product is registered under clinical trial identifier NCT01201343. Target conditions include Multiple Sclerosis, Relapsing, Remitting.

What happened to similar drugs?

20 of 20 similar drugs in Multiple Sclerosis, Relapsing, Remitting were approved

Approved (20) Terminated (0) Active (0)
✅Mirabegron + PlaceboAstellas PharmaApproved
✅Solifenacin Succinate + Solifenacin Succinate + Oxybutynin Hydrochloride + PlaceboAstellas PharmaApproved
✅TeclistamabJohnson & JohnsonApproved
✅BortezomibJohnson & JohnsonApproved
✅DaratumumabJohnson & JohnsonApproved
✅Mavenclad®MerckApproved
✅Mavenclad®MerckApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT01142492Pre-clinicalCompleted
NCT01201343ApprovedCompleted

Competing Products

20 competing products in Multiple Sclerosis, Relapsing, Remitting

See all competitors
ProductCompanyStageHype Score
mRNA-1195ModernaPhase 2
0
NEX-20ANanexa ABPhase 1
23
mRNA-2736ModernaPhase 1
0
mRNA-2808ModernaPhase 2
0
Placebo + PirtobrutinibEli LillyPhase 2
27
Abemaciclib, dexamethasone, ixazomib, pomalidomide + Enasidenib, dexamethasone, ixazomib, pomalidomide + Cobimetinib, dexamethasone, ixazomib, pomalidomide + Erdafitinib, dexamethasone, ixazomib, pomalidomide + Venetoclax, dexamethasone, ixazomib, pomalidomide + Daratumumab, dexamethasone, ixazomib, pomalidomide + Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide + Selinexor, dexamethasone, ixazomib, pomalidomideEli LillyPhase 1/2
32
agenT-797MiNK TherapeuticsPhase 1
19
Duloxetine Hydrochloride (HCI) + PlaceboEli LillyPhase 3
40
TemferonGenenta SciencePhase 1/2
14
CT-P44(Daratumumab) + Darzalex Faspro(Daratumumab)CelltrionPhase 3
47
CT-P53 + US-Ocrevus + EU-OcrevusCelltrionPhase 3
47
CS-0777 tablets + CS-0777 tablets + CS-0777 tabletsDaiichi SankyoPhase 1
29
ASP7487, Velcade, DexamethasoneAstellas PharmaPhase 1/2
24
PHE885NovartisPhase 2
27
Mirabegron + PlaceboAstellas PharmaApproved
43
Solifenacin Succinate + Solifenacin Succinate + Oxybutynin Hydrochloride + PlaceboAstellas PharmaApproved
43
Denileukin Diftitox (Ontak)EisaiPhase 1
21
PalonosetronEisaiPhase 2
35
BIW-8962Kyowa KirinPhase 1
21
KRN125(pegfilgrastim), PLR001(plerixafor) + KRN8601(filgrastim), PLR001(plerixafor)Kyowa KirinPhase 2
35